Ascletis Pharma, ASC36_35FDC, ASC36, ASC35, GLP-1, GIP, Amylin, Obesity, Weight Loss, Metabolic Disease, EASD 2026, Peptide Therapy, Long-Acting Therapy

Hong Kong; data presented in Milan, Italy, October 2, 2026 Ascletis Pharma Inc. announced key preclinical data for ASC36_35FDC,...